Note: For those of you with an interest in developing bacterial vaccines, the results of Pfizer’s failed STRIVE S. aureus vaccine have now appeared in print along with an excellent editorial commentary. Deep sigh on this one — please see the updated prior newsletter for the links and the full story. This newsletter is part
This newsletter is part of a series — here are the links to Part 1, Part 2, Part 3, (this one is Part 4), and Part 5. You might also enjoy the discussion of AI-supported discovery in this May 2026 video from Nature. Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning
This newsletter is part of a series — here are the links to Part 1, (this one is Part 2), Part 3, Part 4, and Part 5. Also relevant is the 5 April 2024 newsletter entitled “48,015 → 0: Antibacterial Discovery Is Hard. Really, Really Hard.“ You might also enjoy the discussion of AI-supported discovery in this May 2026 video from
This newsletter is the first of a series — here are the links to Part 2, Part 3, Part 4, and Part 5. You might also enjoy the discussion of AI-supported discovery in this May 2026 video from Nature. Dear All, Today’s theme is a 3-part journey that could be subtitled “Many are called, but few
Dear All: CDC have recently posted this eclectic mixture of funding opportunities that circle the globe! Funding opportunity: CDC-RFA-CK-26-0107 Title: “Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases“ Brief description: Seeks to build capacity in the United States to prevent, detect, and respond to infectious disease threats by building and sustaining
Dear All: Without much fanfare, we have an announcement that PACCARB (the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) is being revived at a 16 June 2026 virtual meeting! Here are the links you need: 19 May 2026 Federal Register notice DHHS webpage about the meeting Date and time: 16 June 2026, 12.30-3.30p ET
Dear All: I have just learned of a recently opened grant program from NNF (Novo Nordisk Foundation) that seeks to fund early-stage proof-of-concept on rapid, minimally invasive and affordable testing for LRTIs ((Lower Respiratory Tract Infections) at the point-of-care in global settings. The grant program actually opened just after ESCMID and I missed the announcement
Dear All (and with thanks to Arjun Srinivasan for co-authoring this wonkish newsletter — prepare yourself! Know also that we’ve written a parallel newsletter entitled “Economic modeling of the value of rapid diagnostics” that discusses the use of modeling to estimate the value of diagnostics in general): Driven by ongoing work to encourage use as
Dear All, The BBC’s Roland Pease has put together a 3-part podcast series on AMR! Each episode is about 30 minutes, perfect for bite-sized listening. Here is my quick sketch of the topics and voices for each episode: Episode 1: From the discovery of penicillin to the rise of resistance Christoph Tang (Oxford) Kevin Outterson
Dear All, You may recall that in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A description of the desired attributes of a drug) as guides for developers (see the 1 Sep 2019 newsletter for the original call for input and the link to the final set of TPPs). These initial TPPs covered: Enteric fever